

8. Literaturverzeichnis

- Airaksinen MM, Kari I, (1981a) β -Carbolines, psychoactive compounds in the mammalian body. Part I: occurrence, origin and metabolism. *Med. Biol.* 59: 21–34
- Airaksinen MM, Kari I, (1981b) β -Carbolines, psychoactive compounds in the mammalian body. Part II Effects. *Med. Biol.* 59: 190–211
- Airaksinen MM, Lecklin A, Saano V, Tuomisto L, Gynther J, (1987) Tremorigenic effect and inhibition of tryptamine and serotonin receptor binding by beta-carbolines. *Pharmacol Toxicol* 60: 5–8
- Azmitia EC & Whitaker-Azmitia PM, (1995) Anatomy, cell biology and plasticity of the serotonergic system. Neuropsychopharmacological implications for the action of psychotropic drugs. In: FE Bloom & DJ Kupfer (Eds), *Psychopharmacology: The fourth generation of progress*: 443–9 New York Raven Press
- Banchelli G, Fantozzi R, Ignesti G, Pirisino R, Raimondi L, Buffoni F, (1983) The amine oxidase of human blood lymphocytes and granulocytes. *Biochem Int* 7: 89–94
- Baron JA, (1986), Cigarette smoking and Parkinson's disease. *Neurology* 36: 1490–5
- Bench CJ; Price GW; Lammertsma AA; Cremer JC; Luthra SK; Turton D; Dolan RJ; Kettler R; Dingemans J; Da-Prada M, (1991) Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. *Eur J Clin Pharmacol* 40: 169–73
- Benowitz NL, Porchet H, Jacob P, (1990) Pharmacokinetics, Metabolism and Pharmacodynamics of nicotine. Wonnacott S, Russel M, Stolerman IP *Nicotine Psychopharmacology: Molecular, Cellular and Behavioural Aspects*. Oxford, England: Oxford university press: 112–57
- Ben-Shlomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, Lees AJ, (1998) Investigation by Parkinson's disease research group of the United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild, Parkinson's disease: further results of randomised trial and confidential inquiring. *BMJ* 316: 1191–6
- Benwell ME, Balfour DJ, Anderson JM, (1990) Smoking-associated changes in the serotonergic systems of discrete region of human brain. *Psychopharm* 102: 68–72
- Berlin I, Said S, Spreux-Varoquaux O, Olivares R, Launay JM, Puech AJ, (1995) Monoamine Oxidase A and B Activities in heavy smokers. *Biol Psych* 38: 756–61
- Berman SB, Hastings TG, (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implication for Parkinson's disease. *J Neurochem* 73: 1127–37
- Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F, (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. *J Neurol Sci* 20: 415–55
- Bond PA, Cundall RL, (1977) Properties of monoamine oxidase (MAO) in human blood platelets, plasma, lymphocytes and granulocytes. *Clin Chim Acta* 80: 317–26

- Bosin TR, Borg S, Faull KF, (1989) Harman in rat brain, lung and human CSF: Effect of alcohol consumption. *Alcohol* 5: 505–11
- Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72: 248–54
- Breyer-Pfaff U, Wiatr G, Stevens I, Gaertner HJ, Mundle G, Mann K, (1996) Elevated norharman plasma levels in alcoholic patients and controls resulting from tobacco smoking. *Life Sci* 58: 1425–32
- Brossi A, (1993) Mammalian alkaloids II. The alkaloids 43: 119–83
- Buckholtz NS, Boggan WO, (1977) Monoamine oxidase inhibition in brain and liver produced by β -Carbolines: Structure-activity relationships and substrate specificity. *Biochem. Pharmacol.* 26: 1991–6
- Buffoni F, (1995) Semicarbazide-sensitive amine oxidases: some biochemical properties and general considerations. *Prog Brain Res* 106: 323–31
- Cadenas E, Davies KJ, (2000) Mitochondrial free radical generation, oxidative stress, and aging. *Free Radic Biol Med* 29: 222–30
- Callingham BA, Crosbie AE, Rous BA, (1995) Some aspects of the pathophysiology of semicarbazide-sensitive amine oxidase enzymes. *Prog Brain Res* 106: 305–21
- Carr LA, Basham JK, (1991) Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain. *Life Sci* 48: 1173–7
- Centers for Disease Control and Prevention. Smoking-attributable mortality, morbidity, and economic costs. <http://www.cdc.gov/tobacco/sammec>
- Cesura AM, Pletscher A, (1992) The new generation of monoamine oxidase inhibitors. *Prog. Drug Res.* 38: 171–297
- Checkoway H & Nelson LM, (1999) Epidemiologic approaches to the study of Parkinson's disease etiology. *Epidemiology* 10: 327–36
- Chen K, Wu HF, Shih JC, (1993) The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical *J Neurochem* 61: 187–90
- Cheng YC, Prusoff WH, (1973) Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 per cent inhibition IC_{50} of an enzymatic reaction. *Biochemical Pharmacology* 22: 3099–108.
- Chiueh CC, Huang SJ, Murphy DL, (1992) Enhanced hydroxyl radical generation by 2'-methyl analog of MPTP: suppression by clorgyline and deprenyl. *Synapse* 11: 346–8
- Craig DA, (1993) The Cheng-Prusoff relationship: Something lost in the translation. *Trends Pharmacol Sci* 14: 89–91
- Chiueh CC, Krishna G, Tulsi P, Obata T, Lang K, Huang S-J, Murphy DJ, (1992a) Intracranial microdialysis of salicylic acid to detect radical generation through dopamine autooxidation in the caudate nucleus. *Free Radic Biol Med* 13: 641–50
- Da Prada M, Cesura AM, Launay JM, Richards JG, (1988) Platelets as a model for neurones? *Experientia* 2: 115–26.

- Deutsches Krebsforschungszentrum (Hrsg), (2006) Deutschland benötigt ein Bundesgesetz für eine rauchfreie Gastronomie. Heidelberg.
- Donaldson IL, (1989) Alcohol, alcohol. *Alcohol* 24: 263–4
- Donnelly CH, Murphy DL, (1977) Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. *Biochem Pharmacol* 26: 853–8
- Eisenhofer G, (2001) The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. *Pharmacol Ther* 91: 35–62
- Essman WB, (1977) Serotonin and monoamine oxidase in mouse skin: effects of cigarette smoke exposure. *J Med* 8: 95–101
- Fahn S, Cohen G, (1992) The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. *Am Neurol* 32: 804–12
- Fekkes D, Bode WT, (1993) Occurrence and partition of the carboline norharman in rat organs. *Life Sci* 52: 2045–54
- Feyerabend C, Russel MA, (1990) A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids. *J Pharm* 42: 450–3
- Forth W, Henschler D, Rummel W, Starke K, (1996) *Lehrbuch der Pharmakologie* Wissenschaftsverlag Mannheim/Leipzig/Wien/Zürich
- Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D., Wolf AP, Warner D, Zezulkova I., Cilento R, (1996) Inhibition of monoamine oxidase B in the brains of smokers. *Nature* 379: 733–6.
- Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Wolf AP, Warner D, Cilento R, (1998) Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. *J Addict Dis* 17: 23–34
- Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulkova I, Wolf AP, (1996a) Brain monoamine oxidase A inhibition in cigarette smokers. *Proc Natl Acad Sci U S A*. 93: 14065–9
- Fowler JS, Logan J, Volokow ND, (2003) Low monoamine oxidase in peripheral organs in smokers. *PNAS* 100: 11600–5
- Fowler JS, Wang GJ, Volkow ND, Franceschi D, Logan J, Pappas N, (2000) Maintenance of brain monoamine oxidase B inhibition in smokers after an overnight cigarette abstinence. *Am. J. Psych* 1: 325–9
- Fratiglioni L, Wang HX, (2000) Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. *Behav Brain Res* 113: 117–20
- Frazer A, Gerhardt GA, Daws LC, (1999) New views of biogenic amine transporter function: implications for neuropsychopharmacology. *Int. J. Neuropsychopharmacology* 4: 305–20
- Gabrielsson J, Weiner D, (2000) *Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications*, 3rd edition Swedish Pharmaceutical Press, Stockholm, Sweden: 141–53
- Gearhart, Da, Collins MA, Lee JM, Neafsey T, (2000) Increased β -Carbolines 9N-Methyltransferase activity in the frontal cortex in Parkinson's disease. *Neurobiol Dis* 7: 201-11

- Gillis CN, (1985) Peripheral metabolism of serotonin. In: Serotonin and the cardiovascular system. Vanhoutte, PM, Ed. Raven Press, New York, NY: 27–36
- Glassmann H, GF Koob, (1996) Psychoactive Smoke. *Nature* 379: 677–8
- Glover V, Sandler M, (1986) Clinical chemistry of monoamine oxidase. *Cell Biochem Funct* 2: 89–97
- Glover V, Liebowitz J, Armando I, Sandler M, (1982) Beta-Carbolines as selective monoamine oxidase inhibitors: in vivo implications. *J Neural Transm* 54: 209–18
- Goldberg SR, Yasar S, Bergman J, Youdim MB, (1994) Introduction: examination of clinical and preclinical pharmacologic data relating to abuse liability of l-deprenyl (selegiline). *Clin Pharmacol Ther* 56: 721–4
- Goldstein A, (1987) Criteria of a pharmacologic withdrawal syndrome. *Arch Gen Psychiatry* 44: 392–7
- Gorell, JM; Rybicki, BA; Johnson, CC; Peterson, EL, (1999) Smoking and Parkinson's disease, a dose-response relationship *Neurology* 52: 115–9
- Greiner B, Fahndrich C, Strauss S, Rommelspacher H, (1983) Pharmacokinetics of tetrahydronorharmane (tetrahydro-beta-carboline) in rats. *Naunyn Schmiedebergs Arch Pharmacol.* 322: 140–8
- Gründemann D, Liebich G, Kiefer N, Köster S, Schömig E, (1999) Selective substrates for non-neuronal monoamine transporters *Molecular Pharmacology* 56: 1–15
- Gründemann D, Schechinger B, Rappold GA, Schömig E, (1998) Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. *Nat Neurosci* 1: 349–51
- Gunn JA, (1935) Relations between chemical constitution, pharmacological actions and therapeutic uses in the harmine group of alkaloids. *Arch Int Pharmacodyn* 50: 379–96
- Hecht SS, (1999) Tobacco smoke carcinogens and lung cancer. *JNCI* 91: 1194–210
- Haag C, Berkels R, Gründemann D, Lazar A, Taubert D, Schömig E, (2004) The localisation of the extraneuronal monoamine transporter (EMT) in rat brain. *J Neurochem* 88: 291–7
- Halliwell B, (1991) Reaktive Sauerstoffspezies in lebenden Systemen: Herkunft, Biochemie und Bedeutung bei Krankheiten des Menschen in: *Das Glutathionsystem und seine Bedeutung in der Antioxidantien Abwehr* Eds. RG Crystal und D Nolte
- Halliwell B, (1992) Reactive oxygen species and the central nervous system. *J Neurochem* 59: 1609–23
- Hauptmann N, Shih JC, (2001) 2-naphtylamine, a compound found in cigarette smoke decreases both MAO A and B catalytic activity. *Life Sci* 68: 1231–41
- Heatherton TF, Kozlowski LT, Frecher RC, (1991) The Fagerstrom test for nicotine dependence a revision of the Fagerstrom tolerance questionnaire *Br J Addic* 86: 1119–27
- Henningfield JE, Clayton R, Pollin W, (1990) Involvement of tobacco in alcoholism and illicit drug use. *Br J Addic* 85: 279–92
- Herraiz T, Chaparro C, (2006) Human MAO enzyme inhibition by coffee and β -Carbolines norharman and harman isolated from coffee. *Life Sci* 78: 795–802

- Herraiz T, (2004) Relative exposure to beta-carbolines norharman and harman from foods and tobacco smoke. *Food Addit Contam* 21: 1041–50
- Holmstedt B, (1982) Betacarbolines and tetrahydroisoquinolines: historical and ethnopharmacological background. *Prog Clin Biol Res* 90: 3–13
- Honecker H, Rommelspacher H, (1978) Tetrahydronorharmane (tetrahydro-beta-carboline), a physiologically occurring compound of indole metabolism. *Naunyn Schmiedebergs Arch Pharmacol* 305: 135–41
- Horvath G, Sutto Z, Torbati A, Conner GE, Salathe M, Wanner A, (2003) Norepinephrine transport by the extraneuronal monoamine transporter in human bronchial arterial smooth muscle cells. *Am J Phys-Lung Cellular and Molecular Physiology* 285: 829–37
- Hrdina P, (1996) General principles of receptor binding In: *Neuromethods Vol. 4 Receptor binding* (Boulton, G.; Baker, G.; Hrdina, P.; Eds.) Humana Press Inc. New Jersey: 1–22
- Iwasawa Y, Gillis CN, (1974) Pharmacological analysis of norepinephrine and 5-hydroxytryptamine removal from the pulmonary circulation: differentiation of uptake sites for each amine. *J Pharmacol Exp Ther* 188: 386–93
- Jacobs BL, Fornal CA, (1999) Activity of serotonergic neurons in behaving animals. *Neuropsychopharmacology* 21: 9–15
- Jenner P, Olanow CW, (1996) Oxidative stress and the pathogenesis of Parkinson's disease. *Neurology* 47: 161–70
- Johnston JP, (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. *Biochem Pharmacol* 17: 1285–97
- Kahlil AA, Steyn B, Castagnoli N, (2000) Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. *Clinical research in Toxicology* 13: 31–5
- Karhi A, Rantala A, Toivonen H, (1982) Pulmonary inactivation of 5-Hydroxytryptamine is decreased during cigarette smoke ventilation of rat isolated lungs. *Brit J Pharm* 77: 245–8
- Kekuda R, Prasad PD, Wu X, Wang H, Fei YL, Leibach FH, Ganapathy V, (1998) Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. *J Biol Chem* 273: 15971–9
- Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, Kessler RC, (1993) Smoking and major depression. A causal analysis. *Arch Gen Psychiatry* 50: 36–43
- Kerr JS, Sherwood N, Hindmarch I, (1991) Separate and combined effects of the social drugs on psychomotor performance. *Psychopharmacology* 104: 113–9
- Knoll J, Magyar K, (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. *Adv Biochem Psychopharmacol* 5: 393–408
- Von Knorring L, Orelund L, (1985) Personality traits and platelet monoamine oxidase in tobacco smokers. *Psychol Med.* 15: 327–34
- Kotter R, (1994) Postsynaptic interaction of glutamatergic and dopaminergic signals in the striatum. *Prog Neurobiol* 4: 163–96
- Kraml M, (1965) a rapid microfluorometric determination of monoamine oxidase. *Biochem Pharm* 14: 1684–1686

- Levitt P, Pintar JE, Breakefield XO, (1982) Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. *Proc Natl Acad Sci USA* 79: 6385–9
- Lewis AJ, Nicholls PJ, (1972) Effect of inhaled cigarette smoke on content, release and breakdown of histamine in guinea-pig lung. *Life Sci* 11: 1167–71
- Lipper S, Murphy DL, Slater S, Buchsbaum MS, (1979) Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. *Psychopharm (Berl)* 62: 123–8
- Littlewood J, Glover V, Sandler S, Peatfield R, Petty R, Rose FC, (1984) Low platelet monoamine oxidase activity in headache: No correlation with phenolsulphotransferase, succinate dehydrogenase, platelet preparation method or smoking. *J Neuro Neurosurg Psych* 47: 338–43
- Maes M, Meltzer HY, D'Hondt P, Cosyns P, Blockx P, (1995) Effects of serotonin precursors on the negative feedback effects of glucocorticoids on hypothalamic-pituitary-adrenal axis function in depression. *Psychoneuroendocrinology* 20: 149–67
- Marasini B, Biondi ML, Barbesti S, Zatta G, Agostoni A, (1986) Cigarette smoking and platelet function. *Thromb Res* 44: 85–94
- Matsubara K, Collins MA, Akane A, Ikebuchi J, Neafsey EJ, Kagawa M, Shiono H, (1993) Potential bioactivated neurotoxicants, N-methylated β -carbolinium ions, are present in human brain. *Brain Res* 610: 90–6
- Matsubara K, Gonda T, Sawada H, Uezono T, Kobayashi Y, Kawamura T, Ohtaki K, Kimura K, Akaike E, (1998) Endogeneously occurring β -Carboline induces Parkinsonism in non-primate animals a possible causative protoxin in idiopathic Parkinson's disease *J Neurochem* 70: 725–35
- May T, Greube A, Strauss S, Heineke D, Lehmann J, Rommelspacher H, (1994) Comparison of the in vitro binding characteristics of the beta-carbolines harman and norharman in rat brain and liver and in bovine adrenal medulla. *Naunyn Schmiedebergs Arch Pharmacol* 349: 308–17
- May T, Pawlik M, Rommelspacher H, (1991) [3H]harman binding experiments. II: Regional and subcellular distribution of specific [3H]harman binding and monoamine oxidase subtypes A and B activity in marmoset and rat. *J Neurochem* 56: 500–8
- May T, Rommelspacher H, Pawlik M, (1991) [3H]harman binding experiments. I: A reversible and selective radioligand for monoamine oxidase subtype A in the CNS of the rat. *J Neurochem* 56: 490–9
- May T, Strauss S, Rommelspacher H, (1990) [3H]Harman labels selectively and with high affinity the active site of monoamine oxidase (EC 1.4.3.4) subtype A (MAO-A) in rat, marmoset, and pig. *J Neural Transm Suppl* 32: 93–102
- Meller E, Friedmann E, Schweitzer JW, Friedhoff AJ, (1977) Tetrahydro- β -carbolines: Specific inhibitors of type A monoamine oxidase in rat brain. *J Neurochem* 28: 995–1000.
- Merchant C, Tang MX, Albert S, Manly J, Stern Y, Mayeux R, (1999) The influence of smoking on the risk of Alzheimer's disease. *Neurology* 52: 1408–12
- Morens DM, Grandinetti A, Reed D, White LR, Ross GW, (1995) Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? *Neurology* 45: 1041–51

- Murphy DL, Cohen RM Siever LJ Roy B, Karoum F Wyatt RJ Garrick NA Linnoila M, (1983) Clinical and laboratory studies with selective monoamine oxidase-inhibiting drugs. Implications for hypothesized neurotransmitter changes associated with depression and antidepressant drug effects. *Mod Probl Pharmacopsychiat* 19: 287–303.
- Naranjo C, (1979) Psychotropic properties of the harmala Alkaloids. In: Efron DH, Holmstedt Kline B NS (editors): *Ethnopharmacologic research for psychoactive drugs*: New York, Raven Press: 385–91
- Nelson N, (1998) The Family of $\text{NA}^+ \text{Cl}^-$ neurotransmitter transporters. *J Neurochem* 24: 1785–803
- Norman TR Chamberlain KG French MA, (1987) Platelet monoamine oxidase: Low activity in cigarette smokers. *Psychiatry research* 20: 199–205
- Norman TR, Chamberlain KG, French MA, Burrows GD, (1982) Platelet monoamine oxidase activity and cigarette smoking. *J Affect Disord.* 4:73–7
- O'Carroll AM, Fowler CJ, Philipps JP, Tobbia I, Tipton KF, (1983) The deamination of dopamine by human brain monoamine oxidase: Specificity for the two forms in seven brain regions. *Naunyn- Schmiedeberg's Arch Pharmacol* 322: 198–202
- Oreland L Fowler CJ, Schalling D, (1981) Low platelet monoamine oxidase activity in cigarette smokers. *Life Sci* 29: 2511–8
- Ortiz J, Artigas F, (1992) Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rats. *Br J Pharmacol* 105: 941–6
- Ostergren A, Annas A, Skog K, Lindquist NG, Brittebo EB, (2004) Long-term retention of neurotoxic beta-carbolines in brain neuromelanin. *J Neural Transm* 111: 141–57
- Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, Van Broeckhoven C, van Duijn CM, Breteler MM, (1998) Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. *Lancet* 351: 1840–3
- Paczkowski NJ, Vuocolo HE, Bryan-Lluka LJ, (1996) Conclusive evidence for distinct transporters for 5-hydroxytryptamine and noradrenaline in pulmonary endothelial cells of the rat. *Naunyn Schmiedebergs Arch Pharmacol* 353: 423–30
- Parnetti L, Reboldi GP, Santucci C, Santucci A, Gaiti A, Brunetti M, Cecchetti R, Senin U, (1994) Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders. *Aging (Milano)* 6: 201–7
- Pavlin R, Sket D, (1993) Effect of cigarette smoke on brain monoamine oxidase activity. *Farmaceutski Vestnik* 44: 186–92
- Pawlik M, Rommelspacher H, (1988) Demonstration of a distinct class of high-affinity binding site for [^3H] Norharman [^3H] β -carboline in the rat brain. *Eur J Pharmacol* 147: 163–71
- Pfau W, Skog K, (2004) Exposure to β -Carbolines norharman and harman. *J Chromatography B* 802: 115–26
- Pletscher A., Besendorf H. Bächthold HP, Gey KF, (1959) Über pharmakologische Beeinflussung des Zentralnervensystems durch kurzwirkende Monoaminoxidasehemmer aus der Gruppe der Harmala-Alkaloide. *Helv Physiol Acta* 17: 202–14
- Poindexter E.H., R.D. Carpenter, (1962) The Isolation of Harmane and Norharmane from Tobacco and Cigarette Smoke. *Phytochemistry* 1: 215–21

- Poirier J, Donaldson J, Barbeau A, (1985) The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals. *Biochem Biophys Res Commun* 128: 25–33
- Powell JF, Hsu YP, Weyler W, Chen SA, Salach J, Andrikopoulos K, Mallet J, Breakefield XO, (1989) The primary structure of bovine monoamine oxidase type A. Comparison with peptide sequences of bovine monoamine oxidase type B and other flavoenzymes. *Biochem J* 259: 407–13
- Van Praag HM, Kahn RS, Asnis GM, Wetzler S, Brown SL, Bleich A, Korn ML, (1987) Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. *J Affect Disord.* 13: 1–8
- Pranzatelli MR, Snodgrass SR, (1987) Harmala alkaloids and related beta-carbolines: a myoclonic model and antimyoclonic drugs. *Exp Neurol* 96: 703–19
- Precious E, Lyles GA, (1988) Properties of a semicarbazide-sensitive amine oxidase in human umbilical artery. *J Pharm Pharmacol* 40: 627–33
- Racké K, Schworer H, Simson G, (1992) Effects of cigarette smoking or ingestion of nicotine on platelet 5-HT levels in smokers and non-smokers. *Clin Investigations* 70: 201–4
- Riederer P, Sian J, Gerlach M, (2000) Is there neuroprotection in Parkinson syndrome? *J Neurol* 247: 8–11
- Rinne JO, (1987) R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease. *J Neural Transm* 25: 149–55
- Rinne JO, (1991) Nigral degeneration in Parkinson's disease in relation to clinical features. *Acta Neurol Scand* 84: 87–90
- Rommelspacher H, Nanz C, Borbe HO, Fehske KJ, Muller WE, Wollert U, (1981) Benzodiazepine antagonism by harmaline and other beta-carbolines in vitro and in vivo. *Eur J Pharmacol* 70: 409–16
- Rommelspacher H, Barbey M, Strauss S, Greiner B, Fähndrich E, (1982) Is there a correlation between the concentration of β -Carbolines and their pharmacodynamic effects. *Progr. Clin Biol Res* 90: 47–56
- Rommelspacher H, May T, Dufeu P, Schmidt LG, (1994a) Longitudinal observations of monoamine oxidase B in alcoholics: Differentiation of marker characteristics. *Alcohol Clin Exp Res* 18: 1322–9
- Rommelspacher H, May T, Salewski B, (1994) Harman (1-methyl-beta-carboline) is a natural inhibitor of monoamine oxidase type A in rats. *Eur J Pharmacol* 252: 51–59
- Rommelspacher H, May T, Susilo R, (1991a) Beta-carbolines and tetrahydroisoquinolines: detection and function in mammals. *Planta Med* 57: 85–92
- Rommelspacher H, Schmidt LG, May T, (1991) Plasma norharman (beta-carboline) levels are elevated in chronic alcoholics. *Alcohol Clin Exp Res* 15: 553–9
- Russell JA, Kircher KW, (1985) Metabolism of norepinephrine during nerve stimulation in dog trachea. *J Appl Physiol* 59: 1236–41
- Rusted JM, Warburton DM, (1992) Facilitation of memory by post-trial administration of nicotine: evidence for an attentional explanation. *Psychopharmacology* 108: 452–5

- Sällström-Baum S, Hill R, Rommelspacher H, (1996) Harman induced changes of extracellular concentrations neurotransmitters in the nucleus accumbens of rats. *Eur J Pharmacol* 314: 75–82
- Sällström-Baum S, Hill R, Rommelspacher H, (1995) Norharman induced changes of extracellular concentrations neurotransmitters in the nucleus accumbens of rats. *Life Sci* 56: 1715–20
- Sahakian B, Jones G, Levy R, Gray JA, Warburton DM, (1989) The effects of nicotine on attention, information processing and short term memory in patients with dementia of the Alzheimer type. *Br J Psychiatry* 154: 707–800
- Salokangas RK, Vilkmann H, Ilonen T, Taiminen T, Bergman J, Haaparanta M, Solin O, Alanen A, Syvalahti E, Hietala J, (2000) High levels of dopamine activity in the basal ganglia of cigarette smokers. *Am J Psychiatry* 157: 632–4
- Schmidt LG, Dufeu P, Heinz A, Kuhn S, Rommelspacher H, (1997) Serotonergic dysfunction in addiction: effects of alcohol, cigarette smoking and heroin on platelet 5-HT content. *Psych Res* 72: 177–85
- Shoemaker DW, Cummins JT, Bidder TG, Boettger HG, Evans M, (1980) Identification of harman in the rat arcuate nucleus. *Naunyn-Schmiedeberg's Arch. Pharmacol* 310: 227–30,
- Sigg EB, Gyermek L., Hill RT, Yen HCY, (1964) Neuropharmacology of some Harmane derivatives. *Arch Int Pharmacodyn* 149: 164–80
- Silverman, R.B; (1992) in the organic chemistry of Drug Design and Drug Action. Academic press: London
- Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB, (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. *J Neurochem* 56: 978–82
- Soto-Otero R, Mendez-Alvarez E, Riguera-Vega R, Quinoa-Cabana E, Sanchez-Sellero I, Lopez-Rivadulla Lamas M, (1998) Studies on the interaction between 1,2,3,4-tetrahydro-beta-carboline and cigarette smoke: a potential mechanism of neuroprotection for Parkinson's disease. *Brain Res* 802: 155–62
- Sparrow D, O'Connor GT, Young JB, Rosner B, Weiss ST, (1992) Relationship of urinary serotonin excretion to cigarette smoking and respiratory symptoms. The Normative Aging Study. *Chest* 101: 976–80
- Spies CD, Rommelspacher H, Schnapper C, Müller C, Marks C, Berger G, Conrad C, Blum S, Specht M, Hannemann L, Striebel HW, Schaffartzik W, (1995) Betacarbolines in chronic alcoholics undergoing elective tumor resection. *Alcohol Clin Exp Res* 19: 969–76
- Spies CD, Rommelspacher H, Winkler T, Müller C, Brummer G, Funk T, Berger G, Fell M, Blum S, Specht M, Hannemann L, Schaffartzik W, (1996) Betacarbolines in chronic alcoholics following trauma. *Addict Biol* 1: 93–103
- Spies CD, Morciniec P, Lenzenhuber E, Müller C, Marks C, Helling K, Runkel N, Berger G, Blum S, Rommelspacher H, (1998) Beta-carbolines in alcohol-dependent intensive care patients during prophylactics and therapy of alcohol withdrawal syndrome. *Addiction Biol* 3: 281–94
- Squires RF, (1968) Additional evidence for the existence of several forms of mitochondrial monoamine oxidase in the mouse. *Biochem. Pharmacol.* 17: 1401–9

- Stahl SM, (1985) Peripheral models for the study of neurotransmitter receptors in men. *Psychopharmacol Bull.* 21: 663–71
- Storch A, Hwang YI, Gearhart DA, Beach JW, Neadsey EJ, Collins MA, Schwarz J, (2004) Dopamine transporter-mediated cytotoxicity of β -carbolinium derivatives related to Parkinson's disease: relationship to transporter dependent uptake. *J Neurochem* 89: 685–94
- Swan GE, Benowitz NL, Lessov CN Jacob III P, Tyndale RF, Wilhelmsen K, (2005) Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. *Pharmacogenetics and Genomics* 15: 115–25
- Tetrud JW, Langston JW, (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. *Science* 245: 519–22
- The Parkinson study group, (1993) A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. *Ann Neurol* 33: 350–6
- Thorpe LW, Westlund KN, Kochersperger LM, Abell CW, Denney R, (1987) Immunocytochemical localization of monoamine oxidase A and B in human peripheral tissues and brain. *J Histochem Cytochem* 35: 23–32
- Tuncel N, Aydin Y, Tikiz H, (1994) The effect of three products of cigarette smoke (cyanide, thiocyanate and nicotine) on the concentration-response curves of 5-hydroxytryptamine, norepinephrine and epinephrine in the isolated human umbilical veins and arteries. *Pharmacol Toxicol.* 74: 84–8
- Turkish S, Yu PH, Greenshaw AJ, (1988) Monoamine oxidase-B inhibition: a comparison of in vivo and ex vivo measures of reversible effects. *J Neural Transm* 74: 141–8
- Verbeuren TJ, Herman AG, (1989) Pharmacological features of the vasodilation induced by tertatolol in isolated perfused rat kidneys. *Am J Hypertens* 2: 219–22
- Vossler DG, Wyler AR, Wilkus RJ, Gardner-Walker G, Vlcek BW, (1996) Cataplexy and monoamine oxidase deficiency in Norrie disease. *Neurology* 46: 1258–61
- Werneck AL, Alvarenga C, (1999) Genetics, drugs and environmental factors in Parkinson's disease. A case-control study. *Arq Neuropsiquiatr* 57: 347–55
- Westlund KN, Denney RM Kochersperger LM Rose RM Abell CW, (1985) Distinct monoamine oxidase A and B populations in primate brain. *Science* 230: 181–3
- Weyler W, (1989) Monoamine oxidase A from human placenta and monoamine oxidase B from bovine liver both have one FAD per subunit. *Biochem J* 260: 725–9
- Weyler W, Hsu YP, Breakefield XO, (1990) Biochemistry and genetics of monoamine oxidase. *Pharmacol Ther* 47: 391–417
- Yong VW, Perry TL, (1986) Monoamine oxidase B, smoking, and Parkinson's disease. *J Neurol Sci* 72: 265–72
- Yu PH and Boulton AA, (1987) Irreversible inhibition of MAO by some components of cigarette smoke. *Life Sci* 41: 675–82